Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement
- 1 July 1999
- journal article
- Published by Elsevier in Value in Health
- Vol. 2 (4) , 288-294
- https://doi.org/10.1046/j.1524-4733.1999.24003.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) StudyThrombosis Research, 1998
- Economics of thromboprophylaxis in total hip replacement surgery.PharmacoEconomics, 1997
- Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis A feasibility and health economic study in an outpatient settingJournal of Internal Medicine, 1996
- Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparinBritish Journal of Surgery, 1996
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- EnoxaparinPharmacoEconomics, 1996
- Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placeboThe Lancet, 1996
- Low Molecular Weight versus Unfractionated HeparinPharmacoEconomics, 1995
- Prevention of Deep-Vein Thrombosis following Total Hip Replacement Surgery with Enoxaparin versus Unfractionated Heparin: A Pharmacoeconomic EvaluationAnnals of Pharmacotherapy, 1994
- Prophylaxis for Venous Thromboembolism in Hip Fracture SurgeryPharmacoEconomics, 1994